Anlotinib is a multitargeted TKI that blocks VEGFR, PDGFR, FGFR and c-Kit with broad-spectrum antiangiogenic activities.15 Mechanistically, anlotinib potentially synergizes with ICIs by reprogramming the tumor microenvironment (TME) and downregulating PD-L1 expression in preclinical models.16,17 Additionally, as an antiangiogenic agent, anlotinib can enhance the delivery of chemotherapy drugs by inducing tumor vascular normalization.18 Therefore, anlotinib may be a promising combination partner with ICIs and chemotherapy. The gene discussed is PDGFRB; the disease is neoplasm.